Citi expects shares of PTC Therapeutics (PTCT) to be under pressure after uniQure (QURE) reported Phase 1/2 date of its AMT130 gene therapy for Huntington’s disease, which demonstrated a 75% disease slowing at 36 months. The data are “very compelling” and set a “high bar” in Huntington’s, the analyst tells investors in a research note. Citi believes the AMT130 data raise questions as to whether PTC’s data for votoplam will be sufficient. It keeps a Neutral rating on PTC with a $50 price target. The stock in early trading is down 3% to $58.70.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics down 3% after uniQure Huntington’s disease data
- PTC Therapeutics participates in a conference call with Truist
- PTC Therapeutics Completes Study on Vatiquinone for Friedreich Ataxia in Young Children
- PTC Therapeutics price target lowered to $71 from $76 at Morgan Stanley
- PTC Therapeutics: Buy Rating Affirmed Amid Temporary Weakness and Promising Pipeline